The main finding of the study is represented by a steeper decline of the MDRS score in the group of PD-GBA1 treated with STN-DBS than in the other three groups: non-GBA1 carriers treated with DBS, non-GBA1 carriers not treated with DBS, and PD-GBA1 not treated with DBS. This evidence concerns the gene GBA1 and Parkinson disease.